Company: GRCE
Filing Date: 2025-02-10
Form Type: 8-K
Source: 0001140361-25-003645
Chunk: 1

Company: Grace Therapeutics, Inc.
Filing Date: 2025-02-10
Form: 8-K
Item: Item 1.01
Chunk 1
---
 expire on 5:00 p. m. (New York City time) on the earlier of (i) the 60th day after the date theU. S. Food and Drug Administration approves the New Drug Application for GTx-104 and
(ii) September 25, 2028. The Common Warrants are being offered and sold at a purchase price of $0.125 per Common Warrant, which purchase price is included in the offering price per Share and Pre-Funded Warrant issued in the Offering.

TD Securities (USA) LLC acted as placement agent for the Offering. The Company has agreed to pay the placement agent customary placement fees in its capacity as
placement agent for the sale of the Company’s securities to certain of the Investors.

The net proceeds to the Company from the Offering are expected to be approximately $13.8 million, after deducting fees and expenses. The Offering is
expected to close on February 11, 2025 (the “ Closing Date”), subject to the satisfaction of customary closing conditions.

Pursuant to the terms of the Registration Rights Agreement, the Company has agreed to register for resale the Shares and the Warrant Shares. The Company
has agreed to use reasonable best efforts to cause the registration statement covering the resale of the securities described above to be declared effective as promptly as possible after the filing thereof, but no later than the earlier of (a) the
60th calendar day following the initial filing date of the initial registration statement if the Securities and Exchange Commission (the “ SEC”) notifies the Company that it will “review” the initial registration statement and (b) the fifth business
day after the date the Company is notified by the SEC that the initial registration statement will not be “reviewed” or will not be subject to further review. Failure by the Company to meet the filing deadlines and other requirements set forth in
the Purchase Agreements may subject the Company to certain damages. The Company also agreed to use reasonable best efforts to keep such registration statement effective until the earlier of the date the Shares and the Warrant Shares covered by such
registration statement have been sold or may be resold pursuant to Rule 144 without restriction. The Company has agreed to be responsible for all fees and expenses incurred in connection with the registration of the Shares and the Warrant Shares.

Pursuant to the terms of the Purchase Agreements, the Company may not, subject to certain exceptions, until the later of (a) 90 days from the Closing Date
and (b)